Abbott (ABT) and UK-based Reckitt's Mead Johnson were cleared by a jury Thursday of responsibility for a young boy's intestinal disease in a lawsuit over baby formulas for premature babies, according to multiple media reports.
Lawyers for the plaintiff during the five-week trial in a Missouri state court urged jurors to award more than $6.2 billion, Reuters reported.
The companies still face over 1,000 lawsuits alleging their baby formulas can cause necrotizing enterocolitis, an ailment that can cause deaths or brain damage, Bloomberg reported.
Abbott did not immediately reply to MT Newswires' request for comment.
"The decision reinforces what we, the medical community and regulatory bodies have said: that preterm infant nutrition products are safe," news outlets cited the company as saying in a statement.
Shares of the pharmaceutical company were up over 5% in recent Friday premarket activity.
Price: 113.46, Change: -0.99, Percent Change: -0.87
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。